Els van de Vijver

112 REFERENCES: 1. Andrews JM, Travis SP, Gibson PR, Gasche C. Systematic review: does concurrent therapy with 5-ASA and immunomodulators in inflammatory bowel disease improve outcomes? Aliment Pharmacol Ther. 2009;29(5):459-69. 2. Calsbeek H, Rijken M, Bekkers MJ, Kerssens JJ, Dekker J, van Berge Henegouwen GP. Social position of adolescents with chronic digestive disorders. Eur J Gastroenterol Hepatol. 2002;14(5):543-9. 3. Engstrom I. Psychological problems in siblings of children and adolescents with inflammatory bowel disease. Eur Child Adolesc Psychiatry. 1992;1(1):24-33. 4. van Langenberg DR, Gibson PR. Systematic review: fatigue in inflammatory bowel disease. Aliment Pharmacol Ther. 2010;32(2):131-43. 5. Hindryckx P, Laukens D, D'Amico F, Danese S. Unmet Needs in IBD: the Case of Fatigue. Clin Rev Allergy Immunol. 2017. 6. Van de Vijver E, Van Gils A, Beckers L, Van Driessche Y, Moes ND, van Rheenen PF. Fatigue in children and adolescents with inflammatory bowel disease. World J Gastroenterol. 2019;25(5):632-43. 7. Loonen HJ, Derkx BH, Otley AR. Measuring health-related quality of life of pediatric patients. J Pediatr Gastroenterol Nutr. 2001;32(5):523-6. 8. Pirinen T, Kolho KL, Simola P, Ashorn M, Aronen ET. Parent and self-report of sleep- problems and daytime tiredness among adolescents with inflammatory bowel disease and their population-based controls. Sleep. 2010;33(11):1487-93. 9. Rogler D, Fournier N, Pittet V, Buhr P, Heyland K, Friedt M, et al. Coping is excellent in Swiss Children with inflammatory bowel disease: Results from the Swiss IBD cohort study. J Crohns Colitis. 2014;8(5):409-20. 10. Bager P. Fatigue and acute/chronic anaemia. Dan Med J. 2014;61(4):B4824. 11. Aomatsu T, Yoden A, Matsumoto K, Kimura E, Inoue K, Andoh A, et al. Fecal calprotectin is a useful marker for disease activity in pediatric patients with inflammatory bowel disease. Dig Dis Sci. 2011;56(8):2372-7. 12.Marcus SB, Strople JA, Neighbors K, Weissberg-Benchell J, Nelson SP, Limbers C, et al. Fatigue and health-related quality of life in pediatric inflammatory bowel disease. Clin Gastroenterol Hepatol. 2009;7(5):554-61. 13. Akobeng AK, Miller V, Firth D, Suresh-Babu MV, Mir P, Thomas AG. Quality of life of parents and siblings of children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1999;28(4):S40-2. 14.Moody G, Eaden JA, Mayberry JF. Social implications of childhood Crohn's disease. J Pediatr Gastroenterol Nutr. 1999;28(4):S43-5. 15.Wells CW, Lewis S, Barton JR, Corbett S. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis. 2006;12(2):123-30. 16. Haisma SM, Verkade HJ, Scheenstra R, van der Doef HPJ, Bodewes F, van Rheenen PF. Time-to-reach Target Calprotectin Level in Newly Diagnosed Patients With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr. 2019;69(4):466-73. 17. Zittan E, Kelly OB, Gralnek IM, Silverberg MS, Hillary Steinhart A. Fecal calprotectin correlates with active colonic inflammatory bowel disease but not with small intestinal Crohn's disease activity. JGH Open. 2018;2(5):201-6. Chapter 6 112